This application-based continuing pharmacy education course provides a journal club-focused discussion for pharmacists and student pharmacists to more adequately understand the current climate of drug approval with regard to diabetes medications. Join us as we focus on the newest GLP-1 agonist to hit the market, semaglutide, and how it compares to previously approved members of this class. Leave this session feeling confident on discussing the true cardiovascular effects of GLP-1 agonists with patients and providers in your practice.
- The BUZZ / News
- Publications
- MarketplaceAutomationCompoundingContamination ControlDelivery & ShippingDistributionFacilitiesFinanceManufacturingMerchandisingPatient CareHighlighted Practice SettingsProfessional DevelopmentProfessional ServicesSoftware
- Business Management, Operations, ERP
- Clinical Monitoring, Surveillance, Insights
- Controlled Substance Reporting
- Clinical Decision Support, Point of Care Reference, Dosing, DUR
- Drug Diversion Monitoring, Diversion Prevention
- Error Prevention, Drug Validation
- eMAR, EMR, EHR, Bedside Verification
- Formulary Management
- IV Workflow Management
- Long-Term Care Operation Management
- Medication Inventory Management & Procurement
- Pharmacy Management Systems, Workflow
- Stewardship Resources (Antibiotic, Opioid, etc)
Unit DoseWorkflow - Multimedia Content
- Career Center
- Market Intelligence
- Company
